{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:52:43Z","timestamp":1790409163005,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01159-8","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:01:37Z","timestamp":1728903697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma"],"prefix":"10.1038","volume":"14","author":[{"given":"Annika","family":"Werly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0756-8378","authenticated-orcid":false,"given":"Mareike","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosima","family":"Zuern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-4642","authenticated-orcid":false,"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Mueller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-1252","authenticated-orcid":false,"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"1159_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1182\/blood.2021011670","volume":"140","author":"I Vaxman","year":"2022","unstructured":"Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140:828\u201338.","journal-title":"Blood"},{"key":"1159_CR2","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020;38:2380\u20139.","journal-title":"J Clin Oncol"},{"key":"1159_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12:129.","journal-title":"Blood Cancer J"},{"key":"1159_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"M-V Mateos","year":"2020","unstructured":"Mateos M-V, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102.","journal-title":"Blood Cancer J"},{"key":"1159_CR5","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023;10:e203\u2013e212.","journal-title":"Lancet Haematol"},{"key":"1159_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126\u201337.","journal-title":"J Clin Oncol"},{"key":"1159_CR7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"M-V Mateos","year":"2016","unstructured":"Mateos M-V, Hern\u00e1ndez M-T, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127\u201336.","journal-title":"Lancet Oncol"},{"key":"1159_CR8","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1182\/blood.2024023880","volume":"143","author":"H Avet-Loiseau","year":"2024","unstructured":"Avet-Loiseau H, Bahlis NJ. Smoldering multiple myeloma: taking the narrow over the wide path? Blood. 2024;143:2025\u20138.","journal-title":"Blood"},{"key":"1159_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-24-0022","volume":"5","author":"IM Ghobrial","year":"2024","unstructured":"Ghobrial IM, Gormley N, Kumar SK, Mateos M-V, Bergsagel PL, Chesi M, et al. Round table discussion on optimal clinical trial design in precursor multiple myeloma. Blood Cancer Discov. 2024;5:146\u201352.","journal-title":"Blood Cancer Discov"},{"key":"1159_CR10","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"1159_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00980-5","volume":"14","author":"NH Abdallah","year":"2024","unstructured":"Abdallah NH, Lakshman A, Kumar SK, Cook J, Binder M, Kapoor P, et al. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 2024;14:9.","journal-title":"Blood Cancer J"},{"key":"1159_CR12","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M-V, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u2013e312.","journal-title":"Lancet Oncol"},{"key":"1159_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.","journal-title":"Blood Cancer J"},{"key":"1159_CR14","doi-asserted-by":"publisher","first-page":"101910","DOI":"10.1016\/j.eclinm.2023.101910","volume":"58","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Kainz S, Schreder M, Zojer N, Hinke A. SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of \u2019biomarker-defined early multiple myeloma\u2019-a systematic review with meta-analysis. eClinicalMedicine. 2023;58:101910.","journal-title":"eClinicalMedicine"},{"key":"1159_CR15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/s41375-022-01529-w","volume":"36","author":"A Visram","year":"2022","unstructured":"Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, et al. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio \u2265100. Leukemia. 2022;36:1429\u201331.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01159-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01159-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01159-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:03:42Z","timestamp":1728903822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01159-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1159"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01159-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EKM reports consulting or advisory role with Amgen, BMS\/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline, and Takeda; honoraria from Amgen, BMS\/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline, and Takeda; research funding from BMS\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, and Takeda; and travel accommodations and expenses from BMS\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline, and Takeda. AV reports consulting and honoraria fees from Sanofi, Pfizer, Janssen, and Forus, and research funding from Janssen. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}